Raising FVE for Mesoblast After Adjusting for AUD as We Await 180 Day Survival Data in AGvHD
We are raising our fair value estimate for no-moat Mesoblast Ltd (MSB AU) to AUD 2.90 from AUD 2.60 previously, after adjusting for the recent...
398 Views
Mesoblast Books First-Half Profit and Moves Closer to FDA Approval in Pediatric AGvHD
No-moat Mesoblast Ltd (MSB AU) achieved a financial milestone in the first six months of fiscal 2018 by posting a maiden net profit after tax of...
122 Views
Human Longevity
At KIS capital we try to keep ourselves at the forefront of technology and innovation, attempting to identify which industries may blossom, and...
513 Views
Aussie Healthcare Daily: 8 Dec 2017
The Aussie Healthcare Daily is a summary of major news and announcements from ASX-listed healthcare companies as well as developments and trends in...
180 Views
Aussie Healthcare Daily: 5 Dec 2017
The Aussie Healthcare Daily is a summary of major news and announcements from ASX-listed healthcare companies as well as developments and trends in...
146 Views